]
Journey Colab featured in Entrepreneur Magazine
Learn more

Developing Psychedelic Therapies for Addiction

imagined brain slices in 2 parts
scroll down

We are developing evidence-based, patent-protected, synthetically-derived psychedelic therapeutics to transform the treatment of addiction, starting with synthetic Mescaline HCl (JOUR-5700) for the treatment of alcohol use disorder.

Journey Colab is a biopharmaceutical company unlocking the science of psychedelics

Our mission is to unlock the promising science behind psychedelics to provide durable remission to patients suffering from addiction

Backed by world class investors

We believe that delivering effective psychedelic treatments for addiction and other mental health disorders will also require medicine-induced behavioral modification therapy and community support.

Our long-term vision includes not just effective psychedelic products but also enabling a healing economy that includes on-the-ground specialists and the infrastructure that supports their work.

About Us
combination of psychedelics, psychotherapy and community support

Addressing Addiction

Journey Colab is developing psychedelic solutions for the treatment of addiction and other mental health disorders, starting with Mescaline HCl (JOUR-5700) for patients with Alcohol Use Disorder (AUD), who are in desperate need of durable remission from this chronic, relapsing condition.

About Our Science
2021 vs 2027 Addiction Levels:
Cost of addiction in 2021 - $15B;
Cost of addiction in 2027 - $30B

20M+

Americans suffer from addiction today. Only 10% receive lasting benefit from current treatments. ~75% of substance use cases are alcohol-related.

~$70B+

in estimated annual expenditure in U.S. on SUD (2020)

80%

of adults with SUD don’t get treatment

~$1T+

in the estimated economic burden in the U.S. from SUD (2022)

Built with Reciprocity in Mind

Through our unique stakeholder structure, we have built an experienced team dedicated to our mission of creating scientifically rigorous and clinically validated treatments and improving equitable access to care. Ten percent of our founding equity is dedicated to sharing success with stakeholders to increase equitable access to care and recruit employees and partnerships.

Our Reciprocity

Get Our Primer


As a result of seeing increased interest in the psychedelics space, we put together a primer (created by Anna Martirosyan, our Head of Special Projects) to give funds, limited partners, and others an overview of the market.

If you're interested in viewing the primer or learning more,
please reach out to us.
We're here to build an ecosystem and we will need people from all sides and walks of life to get involved in this brave new world and healing economy we're building.

Join Our Team

Our diverse team ranges from Indigenous health advocates and groundbreaking academic researchers to former executives of Allergan, Pfizer, and Novo Nordisk.

Join us